Literature DB >> 22711600

The liver-specific tumor suppressor STAT5 controls expression of the reactive oxygen species-generating enzyme NOX4 and the proapoptotic proteins PUMA and BIM in mice.

Ji Hoon Yu1, Bing-Mei Zhu, Gregory Riedlinger, Keunsoo Kang, Lothar Hennighausen.   

Abstract

UNLABELLED: Loss of signal transducer and activator of transcription 5 (STAT5) from liver tissue results in steatosis and enhanced cell proliferation. This study demonstrates that liver-specific Stat5-null mice develop severe hepatic steatosis as well as hepatocellular carcinomas at 17 months of age, even in the absence of chemical insults. To understand STAT5's role as a tumor suppressor, we identified and investigated new STAT5 target genes. Expression of Nox4, the gene encoding the reactive oxygen species (ROS)-generating enzyme NOX4, was induced by growth hormone through STAT5. In addition, the genes encoding the proapoptotic proteins PUMA and BIM were induced by growth hormone through STAT5, which bound to GAS motifs in the promoter regions of all three genes. We further show that STAT5-induced activation of Puma and Bim was dependent on NOX4. Treatment of mice with transforming growth factor-β, an inducer of apoptosis, resulted in cleaved caspase-3 in control but not in liver-specific Stat5-null mice. This study demonstrates for the first time that cytokines through STAT5 regulate the expression of the ROS-generating enzyme NOX4 and key proapoptotic proteins.
CONCLUSION: STAT5 harnesses several distinct signaling pathways in the liver and thereby functions as a tumor suppressor. Besides suppressing the activation of STAT3, STAT5 induces the expression of proapoptotic genes and the production of ROS.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22711600      PMCID: PMC3505809          DOI: 10.1002/hep.25900

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  34 in total

Review 1.  The Bcl-2 apoptotic switch in cancer development and therapy.

Authors:  J M Adams; S Cory
Journal:  Oncogene       Date:  2007-02-26       Impact factor: 9.867

2.  The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence.

Authors:  Frédérick A Mallette; Marie-France Gaumont-Leclerc; Gerardo Ferbeyre
Journal:  Genes Dev       Date:  2007-01-01       Impact factor: 11.361

3.  Normal growth and development in the absence of hepatic insulin-like growth factor I.

Authors:  S Yakar; J L Liu; B Stannard; A Butler; D Accili; B Sauer; D LeRoith
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

4.  Loss of sexually dimorphic liver gene expression upon hepatocyte-specific deletion of Stat5a-Stat5b locus.

Authors:  Minita G Holloway; Yongzhi Cui; Ekaterina V Laz; Atsushi Hosui; Lothar Hennighausen; David J Waxman
Journal:  Endocrinology       Date:  2007-02-22       Impact factor: 4.736

5.  PUMA expression is significantly reduced in human cutaneous melanomas.

Authors:  Alison M Karst; Derek L Dai; Magdalena Martinka; Gang Li
Journal:  Oncogene       Date:  2005-02-03       Impact factor: 9.867

Review 6.  Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B.

Authors:  Lothar Hennighausen; Gertraud W Robinson
Journal:  Genes Dev       Date:  2008-03-15       Impact factor: 11.361

7.  Hypoxia and defective apoptosis drive genomic instability and tumorigenesis.

Authors:  Deirdre A Nelson; Ting-Ting Tan; Arnold B Rabson; Diana Anderson; Kurt Degenhardt; Eileen White
Journal:  Genes Dev       Date:  2004-08-16       Impact factor: 11.361

8.  STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression.

Authors:  Qian Zhang; Hong Y Wang; Xiaobin Liu; Mariusz A Wasik
Journal:  Nat Med       Date:  2007-10-07       Impact factor: 53.440

9.  Loss of signal transducer and activator of transcription 5 leads to hepatosteatosis and impaired liver regeneration.

Authors:  Yongzhi Cui; Atsushi Hosui; Rui Sun; Kezhen Shen; Oksana Gavrilova; Weiping Chen; Margaret C Cam; Bin Gao; Gertraud W Robinson; Lothar Hennighausen
Journal:  Hepatology       Date:  2007-08       Impact factor: 17.425

10.  Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction.

Authors:  Miriam Erlacher; Verena Labi; Claudia Manzl; Günther Böck; Alexandar Tzankov; Georg Häcker; Ewa Michalak; Andreas Strasser; Andreas Villunger
Journal:  J Exp Med       Date:  2006-12-18       Impact factor: 14.307

View more
  19 in total

1.  NADPH Oxidases in Chronic Liver Diseases.

Authors:  Joy X Jiang; Natalie J Török
Journal:  Adv Hepatol       Date:  2014-11-30

2.  Janus Kinase 2 (JAK2) Dissociates Hepatosteatosis from Hepatocellular Carcinoma in Mice.

Authors:  Sally Yu Shi; Cynthia T Luk; Stephanie A Schroer; Min Jeong Kim; David W Dodington; Tharini Sivasubramaniyam; Lauren Lin; Erica P Cai; Shun-Yan Lu; Kay-Uwe Wagner; Richard P Bazinet; Minna Woo
Journal:  J Biol Chem       Date:  2017-01-18       Impact factor: 5.157

3.  Adipocyte JAK2 mediates spontaneous metabolic liver disease and hepatocellular carcinoma.

Authors:  Kevin C Corbit; Camella G Wilson; Dylan Lowe; Jennifer L Tran; Nicholas B Vera; Michelle Clasquin; Aras N Mattis; Ethan J Weiss
Journal:  JCI Insight       Date:  2019-08-08

Review 4.  Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma.

Authors:  Jinah Choi; Nicole L B Corder; Bhargav Koduru; Yiyan Wang
Journal:  Free Radic Biol Med       Date:  2014-05-06       Impact factor: 7.376

5.  {2-[1-(3-Methoxycarbonylmethyl-1H-indol-2-yl)-1-methyl-ethyl]-1H-indol-3-yl}-acetic Acid Methyl Ester Inhibited Hepatocellular Carcinoma Growth in Bel-7402 Cells and Its Resistant Variants by Activation of NOX4 and SIRT3.

Authors:  Ye Li; Wenjing Wang; Xiaoxue Xu; Shiyue Sun; Xiaoyu Xu; Xian-jun Qu
Journal:  Biomed Res Int       Date:  2015-04-15       Impact factor: 3.411

Review 6.  Oxidative metabolism in cancer: A STAT affair?

Authors:  Jérome Bourgeais; Valérie Gouilleux-Gruart; Fabrice Gouilleux
Journal:  JAKSTAT       Date:  2013-08-12

7.  NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells.

Authors:  A K Jayavelu; J P Müller; R Bauer; S-A Böhmer; J Lässig; S Cerny-Reiterer; W R Sperr; P Valent; B Maurer; R Moriggl; K Schröder; A M Shah; M Fischer; S Scholl; J Barth; T Oellerich; T Berg; H Serve; S Frey; T Fischer; F H Heidel; F-D Böhmer
Journal:  Leukemia       Date:  2015-08-26       Impact factor: 11.528

8.  GH directly inhibits steatosis and liver injury in a sex-dependent and IGF1-independent manner.

Authors:  Andre Sarmento-Cabral; Mercedes Del Rio-Moreno; Mari C Vazquez-Borrego; Mariyah Mahmood; Elena Gutierrez-Casado; Natalie Pelke; Grace Guzman; Papasani V Subbaiah; Jose Cordoba-Chacon; Shoshana Yakar; Rhonda D Kineman
Journal:  J Endocrinol       Date:  2021-01       Impact factor: 4.286

9.  STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia.

Authors:  Wolfgang Warsch; Eva Grundschober; Angelika Berger; Lars Gille; Sabine Cerny-Reiterer; Anca-Sarmiza Tigan; Andrea Hoelbl-Kovacic; Peter Valent; Richard Moriggl; Veronika Sexl
Journal:  Oncotarget       Date:  2012-12

Review 10.  Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse.

Authors:  Jesse D Riordan; Joseph H Nadeau
Journal:  Mamm Genome       Date:  2014-05-07       Impact factor: 2.957

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.